Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab pharmacokinetics and pharmacodynamics in synovial tissue and peripheral blood in active rheumatoid arthritis
2005-003632-22Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in rheumatoid arthritis (RA), sponsored by Roche. Primary endpoint: Change in absolute CD19+ B-cell count in synovial tissue and peripheral blood. Started Mar 2012; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2005-003632-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003632-22.